Armata Wins FDA Breakthrough Therapy Designation For AP-SA02 In Complicated SAB; Stock Up

Armata Pharmaceuticals received FDA Breakthrough Therapy designation for AP-SA02, its intravenously administered multi-phage therapy for use alongside standard treatment in complicated Staphylococcus aureus bacteremia. The designation may accelerate development and regulatory engagement for the candidate, representing a meaningful positive catalyst for the small-cap biotech company.